Left ventricular assist device as destination therapy in doxorubicin-induced cardiomyopathy

Sinan A. Simsir, Shu S. Lin, Laura J. Blue, John P. Gockerman, Stuart D. Russell, Carmelo A. Milano

Research output: Contribution to journalArticlepeer-review

Abstract

Doxorubicin-induced cardiomyopathy is not uncommon and may progress to end-stage heart failure. Treatment of this condition with heart transplantation, however, requires that the primary malignancy be deemed "cured." We present the case of a 55- year-old woman who had doxorubicin-induced cardiomyopathy and non-Hodgkin's lymphoma. The active status of her lymphoma precluded heart transplantation. She had end-stage heart failure and underwent the insertion of a left ventricular assist device as a destination therapy.

Original languageEnglish (US)
Pages (from-to)717-719
Number of pages3
JournalAnnals of Thoracic Surgery
Volume80
Issue number2
DOIs
StatePublished - Aug 1 2005

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Left ventricular assist device as destination therapy in doxorubicin-induced cardiomyopathy'. Together they form a unique fingerprint.

Cite this